Drug Patents owned by Rigel Pharms Inc

1. Drug name - TAVALISSE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8211889 RIGEL PHARMS INC Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Jan, 2026

(3 years from now)

US7538108 RIGEL PHARMS INC Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Mar, 2026

(3 years from now)

US7989448 RIGEL PHARMS INC Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Jun, 2026

(3 years from now)

US8163902 RIGEL PHARMS INC Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Jun, 2026

(3 years from now)

US7449458 RIGEL PHARMS INC Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Sep, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9266912 RIGEL PHARMS INC Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Jan, 2026

(3 years from now)

USRE48898 RIGEL PHARMS INC Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Jan, 2026

(3 years from now)

US9283238 RIGEL PHARMS INC Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Jun, 2026

(3 years from now)

US8912170 RIGEL PHARMS INC Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Jun, 2026

(3 years from now)

US8445485 RIGEL PHARMS INC Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Jun, 2026

(3 years from now)

US8652492 RIGEL PHARMS INC Wet granulation using a water sequestering agent
Nov, 2028

(5 years from now)

US8263122 RIGEL PHARMS INC Wet granulation using a water sequestering agent
Nov, 2030

(7 years from now)

US8771648 RIGEL PHARMS INC (Trimethoxyphenylamino) pyrimidinyl formulations
Jul, 2032

(9 years from now)

US8951504 RIGEL PHARMS INC (trimethoxyphenylamino) pyrimidinyl formulations
Jul, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 17, 2025
New Chemical Entity Exclusivity (NCE) Apr 17, 2023

Drugs and Companies using FOSTAMATINIB DISODIUM ingredient

Market Authorisation Date: 17 April, 2018

Treatment: Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE TABLET;ORAL Prescription
EQ 150MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.